secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2025-07-02T23:59:59+00:00
Accession:  0000950170-25-092964
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular Therapeutics reduces workforce 25%, accelerates wet AMD data to H1 2027; CFO resigns
--------------------------------------------------------------------------------

- CFO Uneek Mehra resigns effective July 15; remains principal financial officer through September 2025 and Q2 filing.
- Phase 3 4FRONT-1 wet AMD trial topline data accelerated to H1 2027 (from H2 2027); 4FRONT-2 started in June 2025.
- Workforce reduction of ~25% of current and planned roles in July 2025, primarily early-stage R&D and support functions.
- Expected $3M in severance costs in Q3 2025; annual cash compensation savings of ~$15M.
- Cash, equivalents and marketable securities of $458M as of March 31, 2025; runway into 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017025092964/0000950170-25-092964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017025092964/fdmt-20250627.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-092964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer